These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33297669)

  • 1. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.
    Leeman-Neill RJ; Soderquist CR; Montanari F; Raciti P; Park D; Radeski D; Mansukhani MM; Murty VV; Hsiao S; Alobeid B; Bhagat G
    Haematologica; 2022 Jan; 107(1):201-210. PubMed ID: 33297669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
    Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
    Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.
    Meer S; Perner Y; McAlpine ED; Willem P
    Histopathology; 2020 Jan; 76(2):212-221. PubMed ID: 31361906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
    Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
    Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.
    Morscio J; Dierickx D; Nijs J; Verhoef G; Bittoun E; Vanoeteren X; Wlodarska I; Sagaert X; Tousseyn T
    Am J Surg Pathol; 2014 Jul; 38(7):875-86. PubMed ID: 24832164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and genetic landscape of plasmablastic lymphoma in Taiwan.
    Chen BJ; Hsieh TH; Yuan CT; Wang RC; Yang CF; Chuang WY; Su YZ; Ho CH; Lin CH; Chuang SS
    Pathol Res Pract; 2024 Jan; 253():155059. PubMed ID: 38160484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmablastic lymphomas show restricted EBV latency profile and
    Ramburan A; Kriel R; Govender D
    Leuk Lymphoma; 2022 Feb; 63(2):370-376. PubMed ID: 34612761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma.
    Miao L; Guo N; Feng Y; Rao H; Wang F; Huang Q; Huang Y
    Histopathology; 2020 Jan; 76(2):201-211. PubMed ID: 31348551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
    Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
    Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
    Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
    Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
    Loghavi S; Alayed K; Aladily TN; Zuo Z; Ng SB; Tang G; Hu S; Yin CC; Miranda RN; Medeiros LJ; Khoury JD
    J Hematol Oncol; 2015 Jun; 8():65. PubMed ID: 26055271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.
    Frontzek F; Staiger AM; Zapukhlyak M; Xu W; Bonzheim I; Borgmann V; Sander P; Baptista MJ; Heming JN; Berning P; Wullenkord R; Erdmann T; Lutz M; Veratti P; Ehrenfeld S; Wienand K; Horn H; Goodlad JR; Wilson MR; Anagnostopoulos I; Lamping M; Gonzalez-Barca E; Climent F; Salar A; Castellvi J; Abrisqueta P; Menarguez J; Aldamiz T; Richter J; Klapper W; Tzankov A; Dirnhofer S; Rosenwald A; Mate JL; Tapia G; Lenz P; Miething C; Hartmann W; Chapuy B; Fend F; Ott G; Navarro JT; Grau M; Lenz G
    Nat Commun; 2021 Aug; 12(1):5183. PubMed ID: 34465776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases.
    Meer S; Perner Y; Willem P
    J Oral Pathol Med; 2022 Feb; 51(2):146-151. PubMed ID: 34910327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmablastic lymphoma: An update.
    Bailly J; Jenkins N; Chetty D; Mohamed Z; Verburgh ER; Opie JJ
    Int J Lab Hematol; 2022 Sep; 44 Suppl 1(Suppl 1):54-63. PubMed ID: 36074710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Loghavi S; Gomez Mediavilla A; Tonda R; Beltran S; Gut M; Pereña Gonzalez A; d'Ámore E; Visco C; Khoury JD; Montes-Moreno S
    Haematologica; 2021 Apr; 106(4):1120-1128. PubMed ID: 32273478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.
    Liu Z; Filip I; Gomez K; Engelbrecht D; Meer S; Lalloo PN; Patel P; Perner Y; Zhao J; Wang J; Pasqualucci L; Rabadan R; Willem P
    Blood Cancer Discov; 2020 Jul; 1(1):112-125. PubMed ID: 33225311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry.
    Pather S; Mashele T; Willem P; Patel M; Perner Y; Motaung M; Nagiah N; Waja F; Philip V; Lakha A; Hale MJ
    Histopathology; 2021 Jul; 79(1):86-95. PubMed ID: 33450085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
    Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
    J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
    Taddesse-Heath L; Meloni-Ehrig A; Scheerle J; Kelly JC; Jaffe ES
    Mod Pathol; 2010 Jul; 23(7):991-9. PubMed ID: 20348882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary plasmablastic lymphoma of the gastrointestinal tract: A series of 13 HIV-negative cases and a review of literature.
    Fu Z; Wang H; Lauwers GY; Jiang K; Jayaratne NL; Bridglal S; Dong N; Wang E; Chen L; Barclift DP; Zhang L
    Ann Diagn Pathol; 2023 Dec; 67():152204. PubMed ID: 37639839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.